Other Events ·
Verastem, Inc. announced preliminary data from the TARGET-D 101 Phase 1/2 trial of VS-7375, an oral KRAS G12D…
VSTMVerastem, Inc.
Verastem, Inc. announced preliminary data from the TARGET-D 101 Phase 1/2 trial of VS-7375, an oral KRAS G12D inhibitor, showing anti-tumor activity in metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic colorectal cancer (mCRC), and advanced non-small cell lung cancer (NSCLC). In mPDAC, 93% of heavily pretreated patients receiving 900 mg QD monotherapy achieved over 50% reduction in the tumor marker CA19-9. The company also announced its intent to collaborate with Erasca, Inc. to evaluate VS-7375 in combination with ERAS-0015 in preclinical models. Key milestones include completing Phase 2 enrollment by the end of 2026 and meeting with the FDA to review Phase 3 pivotal trial designs. Verastem is a biotechnology company developing oncology treatments.